OMERS ADMINISTRATION Corp Purchases Shares of 47,989 Halozyme Therapeutics, Inc. $HALO

OMERS ADMINISTRATION Corp acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 47,989 shares of the biopharmaceutical company’s stock, valued at approximately $3,756,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Horizon Investment Services LLC acquired a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $2,254,000. Chase Investment Counsel Corp acquired a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $2,035,000. Mizuho Markets Americas LLC grew its position in Halozyme Therapeutics by 270.8% during the 4th quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after purchasing an additional 926,526 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Halozyme Therapeutics by 19,326.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 85,476 shares of the biopharmaceutical company’s stock worth $5,753,000 after purchasing an additional 85,036 shares in the last quarter. Finally, Aurora Investment Counsel acquired a new stake in Halozyme Therapeutics during the 2nd quarter valued at $1,427,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 0.6%

Halozyme Therapeutics stock opened at $109.32 on Wednesday. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $109.55. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The stock has a market cap of $12.41 billion, a P/E ratio of 32.63, a P/E/G ratio of 0.44 and a beta of 0.85. The company’s fifty day simple moving average is $84.73 and its 200-day simple moving average is $74.19.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.Halozyme Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period last year, the company earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on HALO shares. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, August 14th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their target price for the company from $83.00 to $110.00 in a report on Friday, August 7th. Finally, Morgan Stanley reduced their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $91.20.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $79,987,320.40. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the sale, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 64,103 shares of company stock valued at $5,226,496 in the last three months. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.